Eden Research PLC Eden Research plc is an AIM-listed public company with intellectual property and expertise in microencapsulation, terpenes and environmentally friendly technologies. We are developing these technologies through innovative research and a series of appropriate commercial production, marketing and distribution partnerships. Based in Cirencester in the UK, we are developing natural solutions to agricultural, animal, human health and industrial problems, with our primary focus being the use of terpenes to create an exciting array of low-risk but effective agricultural chemicals. Eden's products take advantage of the biocidal efficacy of naturally occurring chemicals produced by plant defence mechanisms and, in particular, the antimicrobial properties of terpenes. Terpenes are naturally occurring, low-toxicity botanical substances produced by most plants as part of their defence mechanisms. The initial Eden approach has involved the use of GRAS substances, that is, compounds 'Generally Recogised As Safe' for human consumption or application to food crops. Board of Directors: - Tom Lupton, Non-executive Chairman - Sean Smith, Chief Executive Officer - Alexander John Abrey, Chief Financial Officer - Robin Cridland, Non-executive Director Company No. 03071324
Show more
Cirencester, GB
Size (employees)
4 (est)-20%
Eden Research was founded in 1996 and is headquartered in Cirencester, GB
Report incorrect company information

Eden Research Office Locations

Eden Research has offices in Cirencester and London
Cirencester, GB (HQ)
3 15 Gosditch St
London, GB
Walbrook PR Ltd 4 Lombard Street
Show all (2)
Report incorrect company information

Eden Research Financials and Metrics

Eden Research Financials

Eden Research's revenue was reported to be £1.88 m in FY, 2017

Revenue (FY, 2017)

1.9 m

Gross profit (FY, 2017)

1 m

Gross profit margin (FY, 2017), %


Net income (FY, 2017)

(639.1 k)

EBITDA (FY, 2017)

(780.8 k)

EBIT (FY, 2017)

(780.8 k)

Market capitalization (31-Oct-2017)

18 m

Closing share price (31-Oct-2017)


Cash (31-Dec-2017)

3.7 m
Eden Research's current market capitalization is £18 m.
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017


361 k84 k192.8 k172.5 k91.2 k43.6 k80.2 k99.9 k883.3 k392 k1.9 m

Revenue growth, %


Cost of goods sold

6 k98.7 k28.6 k831.5 k

Gross profit

355 k784.6 k363.4 k1 m
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017


663 k13.1 k81.7 k6.1 k388.5 k340.3 k311.3 k415 k148.4 k1.5 m3.7 m

Accounts Receivable

33.3 k58.9 k64 k54.4 k117.5 k34.4 k145 k86.4 k732 k


206.8 k

Current Assets

770 k190.9 k117.8 k81.4 k483.6 k400.6 k441.1 k477.5 k312.8 k1.8 m4.8 m
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(2.5 m)(2.1 m)(1.7 m)(3.3 m)(3.3 m)(2.3 m)(1.6 m)(3 m)(1.2 m)(1.8 m)(639.1 k)

Cash From Operating Activities

233 k(1.3 m)(431.9 k)(1.8 m)(2.6 m)(1.6 m)(1.2 m)(930.3 k)(104.9 k)(805.8 k)230 k

Cash From Financing Activities

1.5 m1.2 m703.9 k1.8 m3.3 m1.7 m1.4 m1.5 m(30 k)2.5 m2.4 m

Net Change in Cash

658 k(650 k)68.7 k(75.6 k)382.4 k(48.3 k)(28.9 k)103.6 k(266.6 k)1.4 m2.1 m
GBPY, 2017


417.2 k

Financial Leverage

1.2 x
Show all financial metrics

Eden Research Revenue Breakdown

Embed Graph

Eden Research revenue breakdown by business segment: 67.9% from Human health, 30.3% from Agrochemicals and 1.7% from Other

Report incorrect company information

Eden Research Online and Social Media Presence

Embed Graph
Report incorrect company information